Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

My previous session
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Evotec : invests in Exscientia to advance AI-driven drug discovery

share with twitter share with LinkedIn share with facebook
share via e-mail
10/02/2017 | 10:17am CEST

Release date- 29092017 - Hamburg, Germany, Dundee, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and Exscientia Ltd ('Exscientia') today announced that Evotec has made a EUR 15 m investment to take a minority stake in Exscientia.

Through this investment, Evotec becomes the first strategic shareholder in the UK-based company. Exscientia is focused on Artificial Intelligence ('AI')-driven drug discovery and design. With more than 1,800 scientists, Evotec has one of the largest and leading drug discovery platforms in the industry.

Exscientia and Evotec have cooperated since early 2016 to advance small molecules and bispecific small molecules in immuno-oncology. The ongoing success of this partnership was the basis of this expanded and deepened corporate relationship. Exscientia is the world leader in developing and applying AI approaches specifically to design new and better therapeutic molecules in a faster and more cost-effective manner. Exscientia's approach fuses the power of AI with the discovery experience of seasoned drug hunters and chemistry experts. This investment will enable Exscientia to drive higher value partner programmes and expand discovery on its automated design platform.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, said: 'Our investment in Exscientia represents Evotec's single biggest equity placement to date and in, what we feel, is the world leading AI technology company. Working with Exscientia on a joint immuno-oncology project over the past year, we have experienced first-hand how its AI approaches, along with our medicinal chemistry platform, can positively and radically impact drug discovery. We are very excited about the joint potential to leverage AI in chemistry. This investment is also the first time that we can efficiently use our recently awarded EUR 75 m loan facility from the European Investment Bank to bring down cost of capital for such an investment.'

Commenting on the investment, Prof. Andrew Hopkins, Chief Executive Officer of Exscientia, added: 'Exscientia and Evotec have built a close relationship over the past year sharing mutual interest in agile innovation. We are delighted that Evotec has made this investment for a minority equity stake, allowing Exscientia to deliver more drug discovery projects in a rapid and capital efficient manner. I'm also delighted that Dr Mario Polywka, Chief Operating Officer of Evotec, will join Exscientia's Board of Directors, allowing us to benefit from his strong operational expertise in growing successful biotech companies.'

About Exscientia and AI-driven drug discovery

Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, Exscientia is the first company to automate drug design, surpassing conventional approaches.

The innovative platform enables breakthrough productivity gains as well as new approaches to improve drug efficacy. Novel compounds prioritised for synthesis by Exscientia's AI systems simultaneously balance potency, selectivity and pharmacokinetic criteria in order to deliver successful experimental outcomes.

By applying a rapid design-make-test cycle, the Exscientia AI system actively learns from the preceding experimental results and rapidly evolves compounds towards the desired candidate criteria. Exscientia systems learn from both existing data resources and experimental data from each design cycle. The principle is similar to how a human would learn, but the AI process is far more effective at identifying and assimilating multiple subtle and complex trends to balance potency, selectivity and pharmacokinetic criteria. As a result, the AI-driven process is more likely to achieve the end goal and to do this more rapidly and efficiently than traditional human endeavour. Exscientia is collaborating with several leading pharmaceutical companies. In addition to Evotec, partners include Sanofi (metabolic disease), Sumitomo Dainippon Pharma and Sunovion Pharmaceuticals (CNS) and GSK. Exscientia was established as a spinout company from Prof. Andrew Hopkins laboratory at the University of Dundee.


Mark Swallow

Tel: +44 207 638 9571

Email: exscientia@citigatedr.co.uk


Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on EVOTEC AG
08/16EVOTEC AG : reports first half-year 2018 results and corporate updates
08/16EVOTEC : Partner Haplogen Enters into Collaboration with Bayer
08/14EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
08/14EVOTEC AG : Evotec Partner Haplogen Enters Into Collaboration With Bayer
08/14EVOTEC : Partner haplogen enters into collaboration with bayer
08/13EVOTEC AG : Release according to Article 40, Section 1 of the WpHG [the German S..
08/09EVOTEC AG : to report first half-year 2018 results on 09 August 2018
08/09EVOTEC AG : Reports First Half-Year 2018 Results And Corporate Updates
08/09EVOTEC : Reports first half-year 2018 results and corporate updates
08/03EVOTEC : repays 50% of EUR 140 m acquisition loan
More news
News from SeekingAlpha
08/12Evotec AG 2018 Q2 - Results - Earnings Call Slides 
08/12Evotec AG (EVOTF) CEO Werner Lanthaler on Q2 2018 Results - Earnings Call Tra.. 
08/09Evotec AG reports Q2 results 
05/31Evotec forms LAB591 with Arix Bioscience and Fred Hutchinson Cancer Research .. 
05/21Celgene teams up with Evotec to discover new cancer treatments 
Financials (€)
Sales 2018 353 M
EBIT 2018 46,6 M
Net income 2018 34,2 M
Debt 2018 80,3 M
Yield 2018 -
P/E ratio 2018 87,83
P/E ratio 2019 65,01
EV / Sales 2018 8,36x
EV / Sales 2019 7,42x
Capitalization 2 875 M
Duration : Period :
Evotec AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 20,1 €
Spread / Average Target -2,8%
EPS Revisions
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG52.89%3 464
CELLTRION, INC.--.--%29 145
LONZA GROUP18.31%23 390